An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

A new study reveals promising results for a vaccine targeting colorectal and pancreatic cancers. Researchers from the ...

Notoriously hard to treat, pancreatic and colorectal cancers each have high recurrence rates in the years following treatment ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

The "off-the-shelf" vaccine has also shown promising results for pancreatic cancer. Since the U.S. Preventive Services Task ...

The new vaccine, which has shown promise in an early trial involving 20 pancreatic cancer patients and five with bowel cancer ...